$AGMB News

Agomab to Participate in Upcoming Conferences

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Secures US Patent For AGMB-447, Investigational Inhaled Lung-Restricted Small Molecule Inhibitor Of ALK5 For Idiopathic Pulmonary Fibrosis Treatment

Leerink Partners Initiates Coverage On AgomAb Therapeutics with Outperform Rating, Announces Price Target of $36

JP Morgan Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $32

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Morgan Stanley Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $28

Agomab Announces Closing of Initial Public Offering

Agomab indicated to open at $15.50, IPO priced at $16

AgomAb Prices IPO Opens At $14.70/Share; IPO Priced At $16.0/Share

AgomAb Prices IPO Opens At $14.70/Share; IPO Priced At $16.0/Share

Reported Earlier, Agomab Prices Initial Public Offering Of 12.5M ADSs At $16.00 Per ADS For $200M Gross Proceeds

Agomab Announces Pricing of Initial Public Offering

AgomAb Therapeutics NV Readies US IPO On Early Promising Results